Lung Cancer News and Research

Latest Lung Cancer News and Research

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

16 Nov 2011

Silibinin stops spread of lung cancer in mice

Tissue with wound-like conditions allows tumors to grow and spread. In mouse lung cancer cells, treatment with silibinin, a major component of milk thistle, removed the molecular billboards that signal these wound-like conditions and so stopped the spread of these lung cancers, according to a recent study published in the journal Molecular Carcinogenesis.

16 Nov 2011

Encouraging results from KAEL-GemVax GV1001 Phase II trial on NSCLC

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that results from a Phase II trial (CTN-2006) in Stage III non-small cell lung cancer (NSCLC) patients vaccinated with the telomerase peptide GV1001 after chemoradiotherapy and an 8-year update from a phase I/II trial have been published in the November issue of Clinical Cancer, the journal of the American Association for Cancer Research.

15 Nov 2011

Radon exposure may increase risk of non-melanoma skin cancer

A new study published this week suggests that a link may exist between radon exposure and non-melanoma skin cancer.

15 Nov 2011

Women with inflammatory breast cancer now have a chance of treatment

Women with the deadliest and rarest form of breast cancer now have a chance of treatment where once their options were severely limited, thanks to a new discovery by George Mason University researchers.

15 Nov 2011

Surgery to treat lung cancer would increase survival rates

Many more lung cancer patients would survive for longer if they had surgery to remove the disease, according to research published in the European Journal of Cancer.

14 Nov 2011

Cerulean to present positive CRLX101 progression-free survival time results at 2011 AACR-NCI-EORTC

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the presentation of clinical and non-clinical data on its lead product candidate, CRLX101, at the 2011 AACR-NCI-EORTC International Conference taking place from November 12-16 in San Francisco, California.

14 Nov 2011

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that results from preclinical studies of darinaparsin (Zinapar or ZIO-101), a novel organic arsenic, in prostate cancer were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

14 Nov 2011

Patients with KRAS mutant NSCLC should respond well to antifolates

Patients with non-small cell lung cancer who have mutations in the KRAS gene should respond well to the antifolate class of drugs, according to results of a recent study conducted by Quintiles comparing human lung cancer cell lines and patients.

14 Nov 2011

ArQule, Daiichi Sankyo enter license agreement for development of new AKT inhibitor

ArQule, Inc. and Daiichi Sankyo, Co. Ltd. announced today the execution of a license agreement for the development of a new AKT inhibitor called ARQ 092, the first compound to emerge from the companies' November 2008 agreement to collaborate on research utilizing the AKIP (ArQule Kinase Inhibitor Platform) technology to generate novel, selective and potent small molecule kinase inhibitors.

10 Nov 2011

Combination of azacitidine and entinostat shows promise against NSCLC

A new type of therapy aimed at reversing the gene-silencing that promotes cancer-cell growth has shown promising results in a small clinical trial conducted by researchers at the Johns Hopkins Kimmel Cancer Center.

10 Nov 2011

LCA calls on VA to screen veterans at high risk for lung cancer

Lung Cancer Alliance (LCA) salutes the nation's 22 million Veterans for their service to our country and calls on the Department of Veterans Affairs to institute CT screening for those at high risk for lung cancer.

10 Nov 2011

New epigenetic therapy may treat recurrent metastatic NSCLC

Patients with recurrent metastatic non-small cell lung cancer have a morbid prognosis, but a new epigenetic therapy may have potential in this population, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

10 Nov 2011

JMC launches comprehensive lung cancer program

Recruiting one of the nation's leading specialists in minimally-invasive lung and chest surgery, Jupiter Medical Center (JMC) has launched the first comprehensive program in Palm Beach and Martin counties dedicated to prevention, early detection, treatment and care of patients with lung cancer and other diseases of the chest and lung.

10 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011